{"id":"https://openalex.org/W2886409983","doi":"https://doi.org/10.1080/13696998.2018.1510409","title":"A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-typeRASmetastatic colorectal cancer in the US","display_name":"A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-typeRASmetastatic colorectal cancer in the US","publication_year":2018,"publication_date":"2018-08-09","ids":{"openalex":"https://openalex.org/W2886409983","doi":"https://doi.org/10.1080/13696998.2018.1510409","mag":"2886409983","pmid":"https://pubmed.ncbi.nlm.nih.gov/30091652"},"language":"en","primary_location":{"id":"doi:10.1080/13696998.2018.1510409","doi":"https://doi.org/10.1080/13696998.2018.1510409","is_oa":false,"landing_page_url":"https://doi.org/10.1080/13696998.2018.1510409","pdf_url":null,"source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036641783","display_name":"Christopher N. Graham","orcid":"https://orcid.org/0000-0001-8165-7095","observed_orcids":["https://orcid.org/0000-0001-8165-7095"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Christopher N. Graham","raw_affiliation_strings":["RTI Health Solutions, Research Triangle Park, NC, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RTI Health Solutions, Research Triangle Park, NC, USA;","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011101421","display_name":"Alexandra Christodoulopoulou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexandra Christodoulopoulou","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110564732","display_name":"Hediyyih N. Knox","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hediyyih N. Knox","raw_affiliation_strings":["RTI Health Solutions, Research Triangle Park, NC, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RTI Health Solutions, Research Triangle Park, NC, USA;","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070517090","display_name":"Lorenzo Sabatelli","orcid":"https://orcid.org/0000-0001-7373-9306","observed_orcids":["https://orcid.org/0000-0001-7373-9306"]},"institutions":[{"id":"https://openalex.org/I4210139000","display_name":"Amgen (Switzerland)","ror":"https://ror.org/045wjte67","country_code":"CH","type":"company","lineage":["https://openalex.org/I1320553840","https://openalex.org/I4210139000"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Lorenzo Sabatelli","raw_affiliation_strings":["Amgen GmbH, Zug, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen GmbH, Zug, Switzerland;","institution_ids":["https://openalex.org/I4210139000"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001154948","display_name":"Guy Hechmati","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guy Hechmati","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067302715","display_name":"Tamer Garawin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tamer Garawin","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005968330","display_name":"John H. Strickler","orcid":"https://orcid.org/0000-0001-7579-1175","observed_orcids":["https://orcid.org/0000-0001-7579-1175"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John H. Strickler","raw_affiliation_strings":["Duke University, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University, Durham, NC, USA","institution_ids":["https://openalex.org/I170897317"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5036641783"],"corresponding_institution_ids":["https://openalex.org/I4210120329"],"apc_list":null,"apc_paid":null,"fwci":1.8832,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.88685079,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":97},"biblio":{"volume":"21","issue":"11","first_page":"1075","last_page":"1083"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9229000210762024,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9229000210762024,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.07010000199079514,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/panitumumab","display_name":"panitumumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9760000109672546},{"id":"https://openalex.org/keywords/ras-wild-type","display_name":"RAS wild-type","score":0.9800000190734863},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9010000228881836},{"id":"https://openalex.org/keywords/mfolfox6","display_name":"mFOLFOX6","score":0.9399999976158142},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9210000038146973},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9079999923706055},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.6309999823570251},{"id":"https://openalex.org/keywords/drug-costs","display_name":"drug costs","score":0.3880000114440918}],"concepts":[{"id":"https://openalex.org/C2778332735","wikidata":"https://www.wikidata.org/wiki/Q417775","display_name":"Panitumumab","level":5,"score":0.9582690000534058},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8807872533798218},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8806263208389282},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.6352131366729736},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6231390237808228},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.6200787425041199},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5625114440917969},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.43518009781837463},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41582080721855164},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.3898831307888031},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.24574536085128784},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.22325167059898376}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000077544","descriptor_name":"Panitumumab","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000077544","descriptor_name":"Panitumumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002955","descriptor_name":"Leucovorin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009944","descriptor_name":"Organoplatinum Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017059","descriptor_name":"Models, Econometric","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018631","descriptor_name":"ras Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/13696998.2018.1510409","doi":"https://doi.org/10.1080/13696998.2018.1510409","is_oa":false,"landing_page_url":"https://doi.org/10.1080/13696998.2018.1510409","pdf_url":null,"source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},{"id":"pmid:30091652","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30091652","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medical economics","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8560000061988831,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W1187844298","https://openalex.org/W1512398135","https://openalex.org/W1652638408","https://openalex.org/W1985687068","https://openalex.org/W1994222210","https://openalex.org/W1999130958","https://openalex.org/W2005295931","https://openalex.org/W2005348280","https://openalex.org/W2045916016","https://openalex.org/W2058056848","https://openalex.org/W2085633477","https://openalex.org/W2096552494","https://openalex.org/W2104580737","https://openalex.org/W2108235590","https://openalex.org/W2110046944","https://openalex.org/W2130659077","https://openalex.org/W2134047636","https://openalex.org/W2137900825","https://openalex.org/W2141165931","https://openalex.org/W2148199952","https://openalex.org/W2155840608","https://openalex.org/W2159179344","https://openalex.org/W2161593277","https://openalex.org/W2311784214","https://openalex.org/W2575178171","https://openalex.org/W2605964154","https://openalex.org/W2606920054","https://openalex.org/W2636687439","https://openalex.org/W2712978371"],"related_works":["https://openalex.org/W2045916016","https://openalex.org/W2575178171","https://openalex.org/W1187844298","https://openalex.org/W2095953274","https://openalex.org/W2891256468","https://openalex.org/W2149122513","https://openalex.org/W2402621086","https://openalex.org/W2314901090","https://openalex.org/W2342626985","https://openalex.org/W2394925869"],"abstract_inverted_index":{"AIMS:":[0],"This":[1],"analysis":[2,37,246],"investigated":[3],"the":[4,20,46,82,97,106,156,189,241,244],"cost-effectiveness":[5,36],"of":[6,23,75,87,108,113,141,191,198,207,216,221,243,254,267,278,288],"panitumumab":[7,88,153,192,268],"plus":[8,17],"mFOLFOX6":[9,18],"(oxaliplatin,":[10],"5-fluorouracil,":[11],"and":[12,48,66,71,118,125,139,159,170,179,201,228,235,252,260,272,275],"leucovorin)":[13],"compared":[14,294],"with":[15,25,56,65,77,137,167,187,290,295],"bevacizumab":[16,90],"in":[19,45,96,155,194,219,269],"first-line":[21,60,286],"treatment":[22,61,138,287],"patients":[24,76,289],"wild-type":[26,78,291],"RAS":[27,79,292],"metastatic":[28],"colorectal":[29],"cancer":[30],"(mCRC).":[31],"MATERIALS":[32],"AND":[33],"METHODS:":[34],"The":[35,265],"was":[38,49,165],"developed":[39],"from":[40,81,103,149,152,258],"a":[41,52,211,282],"third-party":[42],"payer":[43],"perspective":[44,164],"US":[47,126,199,217],"implemented":[50],"using":[51,247],"partitioned":[53],"survival":[54,237,274],"model":[55,98],"health":[57,99],"states":[58],"for":[59,285],"(progression-free),":[62],"disease":[63],"progression":[64],"without":[67],"subsequent":[68,115,142],"active":[69,143],"treatment,":[70],"death.":[72],"Survival":[73],"analyses":[74,182],"mCRC":[80,122,293],"PEAK":[83,104],"head-to-head":[84],"clinical":[85],"trial":[86],"vs":[89],"were":[91,130,147,183,224,238,256],"performed":[92],"to":[93,121,132,226],"estimate":[94,133],"time":[95],"states.":[100],"Additional":[101],"data":[102,128,151,262],"informed":[105],"amount":[107],"each":[109],"drug":[110],"consumed,":[111],"duration":[112,140],"therapy,":[114],"therapy":[116],"use,":[117],"toxicities":[119],"related":[120],"treatment.":[123],"Literature":[124],"public":[127],"sources":[129],"used":[131],"unit":[134],"costs":[135,169],"associated":[136],"therapies.":[144],"Utility":[145],"weights":[146],"calculated":[148],"patient-level":[150],"trials":[154],"first-,":[157],"second-,":[158],"third-line":[160],"settings.":[161],"A":[162],"life-time":[163],"taken":[166],"future":[168],"outcomes":[171],"discounted":[172],"at":[173],"3%":[174],"per":[175,213],"annum.":[176],"Scenario,":[177],"one-way,":[178],"probabilistic":[180],"sensitivity":[181],"performed.":[184],"RESULTS:":[185],"Compared":[186],"bevacizumab,":[188],"use":[190],"resulted":[193],"an":[195,202],"incremental":[196,203],"cost":[197,212],"$60,286,":[200],"quality-adjusted":[204],"life-year":[205],"(QALY)":[206],"0.445,":[208],"translating":[209],"into":[210],"QALY":[214],"gained":[215],"$135,391":[218],"favor":[220],"panitumumab.":[222],"Results":[223],"sensitive":[225],"wastage":[227],"dose":[229],"rounding":[230],"assumptions":[231],"modeled.":[232],"LIMITATIONS:":[233],"Progression-free":[234],"overall":[236,273],"extrapolated":[239],"beyond":[240],"follow-up":[242],"primary":[245],"fitted":[248],"parametric":[249],"curves.":[250],"Costs":[251],"quality":[253,277],"life":[255,279],"estimated":[257],"multiple":[259],"different":[261],"sources.":[263],"CONCLUSIONS:":[264],"efficacy":[266],"extending":[270],"progression-free":[271],"improving":[276],"makes":[280],"it":[281],"cost-effective":[283],"option":[284],"bevacizumab.":[296]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-08-22T00:00:00"}